- Home
- QNCX vs AGEN Comparison
QNCX vs AGEN Comparison
Compare QNCX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- AGEN
- Stock Information
- Founded
- QNCX 2012
- AGEN 1994
- Country
- QNCX United States
- AGEN United States
- Employees
- QNCX N/A
- AGEN N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QNCX Health Care
- AGEN Health Care
- Exchange
- QNCX Nasdaq
- AGEN Nasdaq
- Market Cap
- QNCX 44.0M
- AGEN 52.6M
- IPO Year
- QNCX 2019
- AGEN 2000
- Fundamental
- Price
- QNCX $1.02
- AGEN $3.00
- Analyst Decision
- QNCX Strong Buy
- AGEN Buy
- Analyst Count
- QNCX 5
- AGEN 4
- Target Price
- QNCX $8.00
- AGEN $8.00
- AVG Volume (30 Days)
- QNCX 511.8K
- AGEN 814.8K
- Earning Date
- QNCX 05-16-2025
- AGEN 05-12-2025
- Dividend Yield
- QNCX N/A
- AGEN N/A
- EPS Growth
- QNCX N/A
- AGEN N/A
- EPS
- QNCX N/A
- AGEN N/A
- Revenue
- QNCX N/A
- AGEN $103,463,000.00
- Revenue This Year
- QNCX N/A
- AGEN $4.03
- Revenue Next Year
- QNCX N/A
- AGEN $5.57
- P/E Ratio
- QNCX N/A
- AGEN N/A
- Revenue Growth
- QNCX N/A
- AGEN N/A
- 52 Week Low
- QNCX $0.51
- AGEN $1.38
- 52 Week High
- QNCX $2.45
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- QNCX 38.15
- AGEN 62.99
- Support Level
- QNCX $0.98
- AGEN $2.87
- Resistance Level
- QNCX $1.16
- AGEN $3.16
- Average True Range (ATR)
- QNCX 0.09
- AGEN 0.34
- MACD
- QNCX 0.00
- AGEN 0.02
- Stochastic Oscillator
- QNCX 20.04
- AGEN 64.29
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).